plasminogen activator inhibitor 2

Summary

Summary: Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.

Top Publications

  1. ncbi Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators
    Jin Mo Park
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA
    Immunity 23:319-29. 2005
  2. ncbi The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
  3. ncbi Revisiting the biological roles of PAI2 (SERPINB2) in cancer
    David R Croucher
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales, Australia 2010
    Nat Rev Cancer 8:535-45. 2008
  4. ncbi Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin
    Andrea Varro
    Physiological Laboratory, University of Liverpool, Liverpool, England
    Gastroenterology 123:271-80. 2002
  5. pmc The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival
    K M Dougherty
    Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109 0650, USA
    Proc Natl Acad Sci U S A 96:686-91. 1999
  6. ncbi Plasminogen activator system and vascular disease
    Suzanne M Nicholl
    Vascular Biology and Therapeutics Program, Center for Vascular Disease, University of Rochester, New York 14642, USA
    Curr Vasc Pharmacol 4:101-16. 2006
  7. pmc Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells
    G Xiao
    Department of Radiation Oncology, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    Proc Natl Acad Sci U S A 96:3700-5. 1999
  8. ncbi A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity
    Wayne A Schroder
    Queensland Institute of Medical Research, Australian Center for International and Tropical Health, Griffith Medical Research College, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    J Immunol 184:2663-70. 2010
  9. ncbi Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2
    Lee Major
    Queensland Institute of Medical Research, Brisbane, PO Royal Brisbane Hospital, Queensland 4029, Australia
    Exp Cell Res 317:338-47. 2011
  10. ncbi SerpinB2 deficiency modulates Th1⁄Th2 responses after schistosome infection
    W A Schroder
    Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Parasite Immunol 32:764-8. 2010

Research Grants

  1. MACROPHAGE/NEUTROPHIL ELASTASE INHIBITOR
    EILEEN REMOLD O DONNELL; Fiscal Year: 1999
  2. VASOACTIVE HORMONE INDUCED GENES IN DIABETIC VASCULATURE
    EDWARD FEENER; Fiscal Year: 1999
  3. Targeting Placental Pathophysiology in IUGR and Preeclampsia
    Seth Guller; Fiscal Year: 2010

Detail Information

Publications177 found, 100 shown here

  1. ncbi Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators
    Jin Mo Park
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA
    Immunity 23:319-29. 2005
    ..Here we describe key roles for transcription factor CREB, a target for p38 signaling, and the plasminogen activator 2 (PAI-2) gene, a target for CREB, in maintenance of macrophage survival...
  2. ncbi The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
    ..Finally, preclinical studies show that either inhibition of uPA catalytic activity or prevention of uPA binding to its receptor reduces tumor growth, angiogenesis and metastasis...
  3. ncbi Revisiting the biological roles of PAI2 (SERPINB2) in cancer
    David R Croucher
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales, Australia 2010
    Nat Rev Cancer 8:535-45. 2008
    ....
  4. ncbi Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin
    Andrea Varro
    Physiological Laboratory, University of Liverpool, Liverpool, England
    Gastroenterology 123:271-80. 2002
    ..The gastric hormone gastrin regulates acid secretion, gene expression, and the functional development and cellular composition of the gastric mucosa. Using a gene array, we sought to identify major, novel, gastrin-regulated genes...
  5. pmc The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival
    K M Dougherty
    Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109 0650, USA
    Proc Natl Acad Sci U S A 96:686-91. 1999
    ..Finally, crossing PAI-2 -/- with PAI-1 -/- mice to generate animals deficient in both plasminogen activator inhibitors failed to uncover an overlap in function between these two related proteins...
  6. ncbi Plasminogen activator system and vascular disease
    Suzanne M Nicholl
    Vascular Biology and Therapeutics Program, Center for Vascular Disease, University of Rochester, New York 14642, USA
    Curr Vasc Pharmacol 4:101-16. 2006
    ....
  7. pmc Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells
    G Xiao
    Department of Radiation Oncology, Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
    Proc Natl Acad Sci U S A 96:3700-5. 1999
    ..The expression of MEPI in myoepithelial cells may prevent breast cancer malignant progression leading to metastasis...
  8. ncbi A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity
    Wayne A Schroder
    Queensland Institute of Medical Research, Australian Center for International and Tropical Health, Griffith Medical Research College, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia
    J Immunol 184:2663-70. 2010
    ....
  9. ncbi Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2
    Lee Major
    Queensland Institute of Medical Research, Brisbane, PO Royal Brisbane Hospital, Queensland 4029, Australia
    Exp Cell Res 317:338-47. 2011
    ..Using CaSki cells as a source of endogenous SerpinB2, we confirmed that SerpinB2 efficiently binds the proteasomal subunit member β1...
  10. ncbi SerpinB2 deficiency modulates Th1⁄Th2 responses after schistosome infection
    W A Schroder
    Queensland Institute of Medical Research, Brisbane, QLD, Australia
    Parasite Immunol 32:764-8. 2010
    ..SerpinB2-/- mice immunized with soluble egg antigen (SEA) also showed reduced levels of SEA-specific IgG1. SerpinB2 deficiency thus promoted certain Th1 and reduced certain Th2 responses in response to this Th2 immunogen...
  11. ncbi Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis
    Andrea Varro
    Physiological Laboratory, University of Liverpool, Liverpool, United Kingdom
    Cancer Res 64:1695-702. 2004
    ..pylori infection, mediated at least partly by paracrine factors; induction of PAI-2 inhibits cell invasion and apoptosis and is a candidate for influencing the progression to gastric cancer...
  12. ncbi Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis
    Kojiro Ohba
    Department of Urology, Nagasaki University Graduate School of Medicine, Nagasaki, Japan
    J Urol 174:461-5. 2005
    ..However, to our knowledge the clinical significance of PAI-2 and the relationship between the uPA system and TAM in human renal cell carcinoma (RCC) tissues have not been investigated. We investigated and clarified these issues...
  13. ncbi High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer
    Johanna Nordengren
    Department of Obstetrics and Gynecology, University Hospital, SE 221 85 Lund, Sweden
    Int J Cancer 97:379-85. 2002
    ..including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival...
  14. ncbi Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Wollongong NSW, Australia
    Semin Thromb Hemost 37:395-407. 2011
    ..This review readdresses the evidence supporting a role for PAI-2 in fibrinolysis and proteolysis within extracellular environments and includes a review of the many potential intracellular functions attributed to PAI-2...
  15. pmc Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif
    Grant A Darnell
    Australian National Centre for International and Tropical Health and Nutrition, Queensland Institute of Medical Research and University of Queensland, 300 Herston Road, Brisbane, Queensland 4029, Australia
    Mol Cell Biol 23:6520-32. 2003
    ..These results indicate that PAI-2 may enhance Rb's tumor suppressor activity and suggest a potential therapeutic role for PAI-2 against HPV-transformed lesions...
  16. ncbi Effect of lipopolysaccharide from periodontal pathogens on the production of tissue plasminogen activator and plasminogen activator inhibitor 2 by human gingival fibroblasts
    Y Xiao
    School of Dentistry, The University of Queensland, Brisbane, Australia
    J Periodontal Res 36:25-31. 2001
    Both tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) are important proteolysis factors present in inflamed human periodontal tissues...
  17. ncbi Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes
    Jodi A Lee
    School of Biological Sciences, University of Wollongong, Northfields Avenue, Wollongong, New South Wales, Australia
    Thromb Haemost 104:1133-42. 2010
    ....
  18. pmc Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli
    Joanna Boncela
    Institute of Medical Biology, Polish Academy of Sciences, Lodz, Poland
    J Biol Chem 286:43164-71. 2011
    ..This suggests that PAI-2, in endothelial cells induced with inflammatory stimuli, can inhibit proteasome and thus tilt the balance favoring proapoptotic signaling...
  19. ncbi Plasminogen activator inhibitor 2: expression and role in differentiation of epidermal keratinocyte
    Xiaohua Lian
    Department of Cell Biology, Third Military Medical University, Chongqing, 400038, PR China
    Biol Cell 96:109-16. 2004
    b>Plasminogen activator inhibitor 2 (PAI-2) is an enzyme inhibitor which is involved in cell differentiation, tissue growth and regeneration...
  20. ncbi The plasminogen activator inhibitor 2 transcript is destabilized via a multi-component 3' UTR localized adenylate and uridylate-rich instability element in an analogous manner to cytokines and oncogenes
    Stan Stasinopoulos
    Monash University, Australian Centre for Blood Diseases, Melbourne, Victoria, Australia
    FEBS J 277:1331-44. 2010
    ..Hence, post-transcriptional regulation of the PAI-2 mRNA transcript involves an interaction between closely spaced adenylate-uridylate elements in a manner analogous to the post-transcriptional regulation of oncogenes and cytokines...
  21. ncbi A functional Ser(413)/Ser(413) PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus
    Claudia A Palafox-Sanchez
    Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético RSME, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, University of Guadalajara, Jalisco
    Clin Appl Thromb Hemost 15:233-8. 2009
    ..Besides, PAI-2 polymorphism could be related with thrombotic phenomena in systemic lupus erythematosus...
  22. ncbi The role of SerpinB2 in immunity
    Wayne A Schroder
    Queensland Institute of Medical Research, Brisbane, Australia
    Crit Rev Immunol 31:15-30. 2011
    ..However, SerpinB2(-/-) mice were recently shown to generate increased Th1 responses, suggesting that at least one function of SerpinB2 is sculpting of the adaptive immune response...
  23. pmc Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1
    Simon Almeida-Vega
    Physiological Laboratory, School of Biomedical Sciences, University of Liverpool, Liverpool, UK
    Am J Physiol Gastrointest Liver Physiol 296:G414-23. 2009
    ....
  24. pmc Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease
    Chitta S Kasyapa
    Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Blood 107:3693-9. 2006
    ....
  25. ncbi The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Cancer Res 60:636-43. 2000
    ..Knowledge of these factors could be helpful to assess the individual risk of patients, to select various types of adjuvant treatment and to identify patients who may benefit from targeted therapies that are currently being developed...
  26. ncbi The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein
    David Croucher
    School of Biological Sciences, University of Wollongong, New South Wales 2522
    J Biol Chem 281:10206-13. 2006
    ..Furthermore, lack of a direct interaction between PAI-2 and LRP implies that downstream signaling events initiated by PAI-1 may not be activated by PAI-2...
  27. ncbi Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation
    Hong Yu
    Monash University Department of Medicine, Box Hill Hospital, Victoria, Australia
    Blood 99:2810-8. 2002
    ..These results implicate endogenous PAI-2 as a modulator of monocyte adhesion, proliferation, and differentiation...
  28. pmc 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model
    Y Li
    Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, NSW, Australia
    Br J Cancer 86:1197-203. 2002
    ....
  29. ncbi SerpinB2 is an inducible host factor involved in enhancing HIV-1 transcription and replication
    Grant A Darnell
    Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    J Biol Chem 281:31348-58. 2006
    ..This is the first report associating HIV-1 replication with SerpinB2 expression and illustrates that SerpinB2 is a potentially important inducible host factor that significantly promotes HIV-1 replication...
  30. pmc A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization
    Malgorzata Wilczynska
    Department of Medical Biochemistry and Biophysics, Umea University, 901 87 Umea, Sweden
    EMBO J 22:1753-61. 2003
    ..Taken together, our data suggest that the CD-loop functions as a redox-sensitive switch that converts PAI-2 between an active stable monomeric and a polymerogenic conformation, which is prone to form inactive polymers...
  31. ncbi Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters
    Yan J Song
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Gray St, Kogarah, 2217 NSW, Australia
    Cancer Lett 234:176-83. 2006
    ..These ACs are potential candidates for the control of ovarian cancer at the minimum residual disease (MRD) stage...
  32. ncbi Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope
    P J Jensen
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104 6142
    Exp Cell Res 217:65-71. 1995
    ..These studies raise the possibility that PAI-2 may have an intracellular role associated with the terminal stage of keratinocyte differentiation...
  33. ncbi The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Biochem 37:541-8. 2004
    ..The measurement of uPA components, especially in breast cancer, thus has the potential to help with individualised patient management...
  34. ncbi Haemostatic changes in pregnancy
    Benjamin Brenner
    Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, P O Box 9602, Haifa 31096, Israel
    Thromb Res 114:409-14. 2004
    ..Disruption of anticoagulant mechanisms, for example, autoantibodies, to annexin V may increase pregnancy complications in patients with antiphospholipid antibodies (APLA)...
  35. ncbi Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis
    L A Robbie
    Departments of Medicine and Therapeutics and Molecular and Cell Biology, University of Aberdeen, UK
    Br J Haematol 109:342-8. 2000
    ..Leucocyte release of these agents within fibrin deposits may influence the persistence of fibrin and thus the development of multiple organ failure...
  36. ncbi In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells
    M Ranson
    Department of Biological Science, University of Wollongong, Kogarah, NSW, Australia
    Breast Cancer Res Treat 71:149-59. 2002
    ..In conclusion, we have validated, in vitro, the potential of alpha-PAI-2 as a novel therapeutic agent for breast cancer...
  37. ncbi Identification of potentially effective antisense oligodeoxyribonucleotide (ODN) sequences for inhibiting plasminogen activator inhibitor-2 (PAI-2) production by monocytes
    Julia Humphries
    Academic Dept of Surgery, GKT Medical School, Kings College, St Thomas Hospital, London, UK
    Thromb Haemost 88:131-6. 2002
    ..Selecting effective sequences is a problem as prediction of the secondary structure of target mRNA is difficult. This study reports the modification of a cell free system for rapid antisense screening...
  38. ncbi The spontaneous polymerization of plasminogen activator inhibitor type-2 and Z-antitrypsin are due to different molecular aberrations
    Malgorzata Wilczynska
    Department of Medical Biochemistry and Biophysics, Umea University, Sweden
    FEBS Lett 537:11-6. 2003
    ..Rather, PAI-2 exists in a highly polymerogenic conformation and does not require conformational rearrangements before polymerization can take place...
  39. pmc Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2
    B J Allen
    Centre for Experimental Radiation Oncology, St George Cancer Centre, Gray St, Kogarah, NSW 2217, Australia
    Br J Cancer 88:944-50. 2003
    ..Thus, (213)Bi-PAI2 is successful in targeting isolated breast cancer cells and preangiogenic cell clusters. These results indicate the promising potential of (213)Bi-PAI2 as a novel therapeutic agent for micrometastatic breast cancer...
  40. ncbi Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop
    L Jankova
    Initiative in Biomolecular Structure, School of Physics, University of New South Wales, Sydney New South Wales 2052, Australia
    J Biol Chem 276:43374-82. 2001
    ..This torsional change is due to the binding of the P14 threonine of the RCL to the open breach region of PAI-2...
  41. ncbi The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2
    Robert L Medcalf
    Australian Centre for Blood Diseases, Monash University, Prahran, Victoria, Australia
    FEBS J 272:4858-67. 2005
    ..Despite these recent advances in defining the intracellular function of PAI-2, it still remains one of the most mysterious and enigmatic members of the serpin superfamily...
  42. ncbi Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer
    Chang F Qu
    Centre for Experimental Radiation Oncology, Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia
    Clin Exp Metastasis 22:575-86. 2005
    ..We have labeled PAI2 with (213)Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy...
  43. ncbi Structural bases of the redox-dependent conformational switch in the serpin PAI-2
    Sergei Lobov
    Department of Medical Biochemistry and Biophysics, Umea University, SE 901 87 Umea, Sweden
    J Mol Biol 344:1359-68. 2004
    ....
  44. ncbi Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model
    Syed M Abbas Rizvi
    Center for Experimental Radiation Oncology CERO, Division of Cancer Services, St George Hospital, Gray Street, Kogarah, NSW 2217, Australia
    Cancer Biol Ther 5:386-93. 2006
    ..Targeted alpha therapy (TAT) is an experimental therapeutic modality for cancer. Another objective was to compare the in vivo pharmacokinetics using two different chelators to form the radioisotope-protein construct...
  45. ncbi Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines
    Fares Al-Ejeh
    School of Biological Sciences, University of Wollongong, NSW 2522, Australia
    Exp Cell Res 297:259-71. 2004
    ..PAI-2 was subsequently degraded, presumably within lysosomes. This study is the first to provide definitive evidence for uPA/uPAR-mediated PAI-2 endocytosis...
  46. ncbi Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities
    Daniel A Di Giusto
    School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW 2052, Australia
    J Mol Biol 353:1069-80. 2005
    ....
  47. ncbi Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms
    P Mikus
    Department of Cell and Molecular Biology, Umea University, Sweden
    Eur J Biochem 218:1071-82. 1993
    ..Instead, this treatment enhanced the formation of PAI-2 polymers, possibly by the loop-sheet polymerisation mechanism described for alpha 1-antitrypsin...
  48. ncbi Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function
    J L Dickinson
    Queensland Cancer Fund Experimental Oncology Unit, Queensland Institute of Medical Research, Brisbane, Australia
    J Biol Chem 270:27894-904. 1995
    ..The results suggest that intracellular PAI-2 might be an important factor in regulating cell death in TNF-mediated inflammatory processes through inhibition of a proteinase involved in TNF-induced apoptosis...
  49. pmc A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells
    David R Croucher
    School of Biological Sciences, University of Wollongong, NSW 2522, Australia
    Biochem J 408:203-10. 2007
    ..We thus propose a structurally based mechanism for these differences between PAI-1 and PAI-2 and suggest that PAI-2 is able to inhibit and clear uPA activity without initiating mitogenic signalling events through VLDLr...
  50. ncbi Regulation and interactions in the activation of cell-associated plasminogen
    H Myöhänen
    Haartman Institute, University of Helsinki, P O Box 21, 00014, Helsinki, Finland
    Cell Mol Life Sci 61:2840-58. 2004
    ..The functional role of the PAIs is no longer simply to inhibit overexpressed plasminogen activators, and PAI-2 has an unidentified role in the regulation of cell death...
  51. ncbi Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin
    H Ritchie
    Department of Molecular and Cell Biology, University of Aberdeen, UK
    Thromb Haemost 81:96-103. 1999
    b>Plasminogen activator inhibitor 2 (PAI-2) is a major product of activated human monocytes. Here we show that monocytes inhibited u-PA- but not t-PA-mediated fibrinolysis, by secreting PAI-2 into an overlying fibrin clot...
  52. ncbi Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients
    S Borstnar
    Institute of Oncology, Ljubljana, Slovenia
    Clin Breast Cancer 3:138-46. 2002
    ....
  53. pmc Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis
    P H Jensen
    Department of Medical Biochemistry, Aarhus University, Denmark
    Br J Cancer 70:834-40. 1994
    The proteolytic modification of plasminogen activator inhibitor 2 (PAI-2) was studied during apoptosis in the human promyelocytic leukaemic NB4 cell line during treatment with the phosphatase inhibitors okadaic acid and calyculin A as ..
  54. ncbi [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]
    K Mengele
    Klinische Forschergruppe, Frauenklinik der Technischen Universitat Munchen, Ismaninger Str 22, 81675 Munchen
    Hamostaseologie 25:301-10. 2005
    ..Enzymometric and enzymographic tests are actually conducted only in an experimental, preclinical context...
  55. ncbi Effects of platelet-derived growth factor isoforms on plasminogen activation by periodontal ligament and gingival fibroblasts
    H Agis
    Department of Oral Surgery, Medical University of Vienna, Vienna, Austria
    J Periodontal Res 43:334-42. 2008
    ..In the present study we investigated the effect of platelet-derived growth factor isoforms on the plasminogen activator system in periodontal fibroblasts...
  56. ncbi Evidence for an active fibrinolytic system in normal human bone marrow
    N A McWilliam
    Department of Molecular and Cell Biology, University of Aberdeen, Marischal College
    Br J Haematol 93:170-6. 1996
    ..A role for the active fibrinolytic system in normal human bone marrow may be the removal of unnecessary fibrin deposits formed in the cavities of the marrow, in order to maintain flow through this tissue...
  57. ncbi Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells
    A Unlu
    Department of Biochemistry, Medical Faculty, Mersin University, Mersin, Turkey
    Int J Biol Markers 18:147-51. 2003
    ..In conclusion, the potential contribution of TGFbeta1 to tumor invasion may be considered as positive, based on both loss of growth inhibition and stimulation of components of the invasive system of prostate carcinoma...
  58. ncbi Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer
    T Cufer
    Institute of Oncology, Ljubljana, Slovenia
    Int J Biol Markers 18:106-15. 2003
    ..In addition, it pointed to a possible predictive value of these tumor markers for response to adjuvant hormone therapy with tamoxifen, which should be confirmed in further studies...
  59. ncbi Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions
    Carmen Alemán
    Department of Internal Medicine, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Sci (Lond) 105:601-7. 2003
    ..Blockage of fibrin clearance in empyema and complicated parapneumonic effusions was associated with both enhanced levels of PAIs and decreased levels of t-PA...
  60. ncbi [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
    En min Zhao
    Department of Otorhinolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing 100034, China
    Zhonghua Er Bi Yan Hou Ke Za Zhi 38:39-42. 2003
    ....
  61. ncbi Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma
    Borut Stabuc
    University Medical Centre Ljubljana, Division of Internal Medicine, Japljeva 2, 1000 Ljubljana, Slovenia
    Oncol Rep 10:635-9. 2003
    ..25, 17.67, 27.67, 37.77, respectively). Determination of uPA and PAI-1 can provide significant additional prognostic information for melanoma patients...
  62. ncbi Quantitative evaluation of the influence of ovarian steroids on plasminogen activators and inhibitors in human endometrial cells and trophoblasts
    Mamoru Ueyama
    1st Department of Obstetrics and Gynecology, Toho University School of Medicine, Ota, Tokyo, Japan
    Thromb Res 108:235-44. 2002
    ....
  63. ncbi The plasminogen activator system: biology and regulation
    J P Irigoyen
    Friedrich Miescher Institute, Basel, Switzerland
    Cell Mol Life Sci 56:104-32. 1999
    ..Thus, modulation of mRNA stability is an important factor in overall regulation. This review summarizes current understanding of the biology and regulation of genes involved in plasminogen activation at different levels...
  64. ncbi Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma
    Aiqun Xue
    Department of Surgery, The University of Sydney, Sydney, Australia
    Pancreas 36:160-7. 2008
    ..To determine the diagnostic and prognostic significance of growth factors and the urokinase-type plasminogen activator (uPA) system in pancreatic ductal adenocarcinoma (PDAC) using a multigene assay...
  65. ncbi Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum
    H Kliem
    Physiology Weihenstephan, Technical University Munich, 85354 Freising, Germany
    Reproduction 134:535-47. 2007
    ..Immunohistochemistry for MMP-1, MMP-2, MMP-14: an increased staining for MMP-1 and MMP-14 was seen in large luteal cells beginning 24 h after PGF2alpha application. MMP-2 showed a strong increase in staining in endothelial cells at 48 h...
  66. ncbi Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy
    Marianne Coolman
    Department of Obstetrics and Gynaecology, Division of Obstetrics and Prenatal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Obstet Gynecol Reprod Biol 128:22-8. 2006
    ..Haemostasis is a complex balance of activating and inhibitory pathways resulting in coagulation and lysis. Normal pregnancy is associated with hypercoagulation that is even more profound in complicated pregnancies...
  67. ncbi [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks]
    Waldemar Uszyński
    Katedra i Zakład Propedeutyki Medycyny, Bydgoszczy
    Ginekol Pol 75:971-8. 2004
    ..To develop the hypothesis on biochemical mechanism of the placenta accreta and to review the epidemiological information on that complication...
  68. ncbi Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice
    Kasper Almholt
    The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Oncogene 22:4389-97. 2003
    ....
  69. ncbi [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
    Enmin Zhao
    Department of Otolaryngology Head and Neck Surgery, The First Hospital of Peking University, Beijing 100034
    Lin Chuang Er Bi Yan Hou Ke Za Zhi 16:599-602. 2002
    ..The aim of the present study was to evaluate whether the expression of uPA parameters might be of clinical value in squamous cell carcinoma of human larynx as a tumor/biologically defined risk factor...
  70. ncbi A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis
    Xia Wang
    Department of Molecular Genetics, Shanghai Medical School, Fudan University, 200032 Shanghai, P R China
    J Cancer Res Clin Oncol 131:129-36. 2005
    ..In conclusion, the results suggested that the hybrid protein has therapeutic potential for lung carcinoma and other tumors to inhibit tumor invasion and metastasis...
  71. ncbi Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma
    Tamantha K Stutchbury
    School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522, Australia
    Mol Cancer Ther 6:203-12. 2007
    ..This will allow detailed safety evaluation in a second species and for the initiation of human studies...
  72. ncbi NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model
    Masayasu Nishikawa
    Department of Surgery, Weill Medical College of Cornell University, New York, NY, USA
    J Am Coll Surg 199:428-35. 2004
    ..COX-2 also relates to degradation of the extracellular matrix, but the relationship between COX-2 and the plasminogen activator system is unclear...
  73. ncbi Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
    ..Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system...
  74. ncbi Low oxygen concentrations inhibit trophoblast cell invasion from early gestation placental explants via alterations in levels of the urokinase plasminogen activator system
    Gendie E Lash
    Schools of Surgical and Reproductive Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, United Kingdom
    Biol Reprod 74:403-9. 2006
    ..The reduction in the invasive capacity of EVT cultured at 3% oxygen appears to be mediated both by a general inhibition of the PLAU system and a decrease in the number of cells available to invade...
  75. ncbi Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia
    Eva Maria Roes
    Departments of Obstetrics and Gynecology, University Medical Center Nijmegen, Geert Grooteplein 8, 6525 GA Nijmegen, The Netherlands
    Am J Obstet Gynecol 187:1019-25. 2002
    ..The purpose of this study was to evaluate the plasminogen activator system in maternal and umbilical cord plasma in patients with severe preeclampsia compared with control subjects with normotensive pregnancies...
  76. ncbi Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells
    Takuya Akai
    Department of Neurosurgery, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan
    J Neurooncol 59:193-8. 2002
    ..The effect of platelet activating factor (PAF), a potent mediator of inflammatory and immune responses, on this fibrinolytic activity was also examined...
  77. ncbi Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells
    C He
    Department of Molecular Genetics, Shanghai Medical University, Shanghai, 200032, China
    J Cancer Res Clin Oncol 127:180-6. 2001
    ....
  78. ncbi Clinical value of components of the plasminogen activation system in ovarian cyst fluid
    E A Boss
    Department of Obstetrics and Gynecology, University Medical Centre Nijmegen, The Netherlands
    Anticancer Res 22:275-82. 2002
    ....
  79. ncbi Plasminogen activators and inhibitors are transcribed during early macaque implantation
    Q Feng
    Department of Pre-Clinical Sciences, Leicester Warwick Medical School, University Road, Leicester, LE1 9HN, UK
    Placenta 22:186-99. 2001
    ..In conclusion our results suggest that gene expression of PAs and PAIs in early implantation sites are tissue-specific, location-sensitive and function-related...
  80. ncbi Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms
    M Falkenberg
    Department of Vascular Surgery, Sahlgrenska University Hospital, , Sweden
    Eur J Surg 167:10-4. 2001
    ..Reduced activity of tissue plasminogen activator may be responsible for thrombosis in the aneurysm...
  81. ncbi Endothelin-1 promotes proteolytic activity of ovarian carcinoma
    Laura Rosanò
    Laboratory of Molecular Pathology, Regina Elena Cancer Institute, Via delle Messi d Oro 156, 00158 Rome, Italy
    Clin Sci (Lond) 103:306S-309S. 2002
    ....
  82. ncbi Retinoic acid upregulates the plasminogen activator system in human epidermal keratinocytes
    E Braungart
    Department of Dermatology, , , Germany
    J Invest Dermatol 116:778-84. 2001
    ..The activation of the plasminogen activator system may be one mechanism by which all-trans retinoic acid exerts beneficial effects in cutaneous wound healing...
  83. ncbi Do fibrinolytic proteins of human bile derive exclusively from gall bladder?
    D Gil
    Department of Internal Medicine, Silesian Medical University, St Barbara s District Hospital, plac Medykow 1, 41 200 Sosnowiec, Poland
    Med Sci Monit 7:262-3. 2001
    ..In this study we addressed the issue of whether fibrinolytic proteins are presented in gall bladder bile only or in choledochus bile as well...
  84. ncbi Post-transcriptional regulation of gene expression in the plasminogen activation system
    Nunzia Montuori
    Centro di Endocrinologia ed Oncologia Sperimentale CEOS, Consiglio Nazionale delle Ricerche, Naples, Italy
    Biol Chem 383:47-53. 2002
    ..The control of the expression occurs both at transcriptional and post-transcriptional levels. This review is focused on the post-transcriptional regulation of gene expression of all components of the PA system...
  85. ncbi [Serine protease inhibitors in plasma of patients with ulcerative colitis]
    M Swiatkowski

    Przegl Lek 58:67-70. 2001
    ....
  86. ncbi Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin
    Nuria Arroyo De Prada
    Klinische Forschergruppe der Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, German
    Eur J Biochem 269:184-92. 2002
    ..Our results demonstrate that the wild-type sequence of the region around hE in PAI-1 is not a prerequisite for binding to Vn...
  87. ncbi The expression of plasminogen activator system in a rat model of periodontal wound healing
    Y Xiao
    School of Dentistry, The University of Queensland, Brisbane, Australia
    J Periodontol 72:849-57. 2001
    ..The aim of this study was to elucidate the presence of components of the plasminogen activator system during different stages of periodontal wound healing...
  88. ncbi Placenta and myometrium--the two main sources of fibrinolytic components during pregnancy
    M Uszynski
    Department of Propedeutics of Medicine, Ludwik Rydygier Medical University, Bydgoszcz, Poland
    Gynecol Obstet Invest 52:189-93. 2001
    ..Placenta is a known source of some fibrinolytic components in pregnancy. The aim of the present study is to find out whether myometrium can be a parallel source...
  89. ncbi Antigen levels of urokinase type plasminogen activator and its inhibitors in primary breast cancer
    Anna Sałuda-Gorgul
    Department of Biochemistry, Institute of Physiology and Biochemistry, Medical University of Lodz, Poland
    Z Naturforsch C 57:366-71. 2002
    ..The goal of the present study was to evaluate a possible combined prognostic value of the three major components of the u-PA system (u-PA, PAI-1 and PAI-2) in patients with defined histopathological forms of primary breast cancer...
  90. ncbi Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract
    K P Radtke
    Forschungslaboratorien der Behringwerke AG, Marburg Lahn
    Biol Chem Hoppe Seyler 371:1119-27. 1990
    ..These data suggest that the predominant form of PAI-2 in placenta extract is heterogeneous and of high molecular mass, containing complexes in which vitronectin is covalently bound to PAI-2 by disulfide bridges...
  91. ncbi A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9)
    J Sun
    Department of Medicine, Monash Medical School, Clive Ward Centre, Box Hill Hospital, Box Hill 3128, Australia
    J Biol Chem 272:15434-41. 1997
    ..Such "ovalbumin" serpins include the human proteinase inhibitors 6 (PI-6), 8 (PI-8), and 9 (PI-9), plasminogen activator inhibitor 2, and the monocyte/neutrophil elastase inhibitor...
  92. ncbi Effects of menstrual cycle on periodontal health and gingival crevicular fluid markers
    Sema Becerik
    Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey
    J Periodontol 81:673-81. 2010
    ....
  93. ncbi Fibrinogen and fibrin structure and functions
    M W Mosesson
    The Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI 53201 2178, USA
    J Thromb Haemost 3:1894-904. 2005
    ..vii) Leukocyte binding to fibrin(ogen) via integrin alpha(M)beta2 (Mac-1), which is a high affinity receptor on stimulated monocytes and neutrophils...
  94. ncbi Gene microarray analysis reveals interleukin-5-dependent transcriptional targets in mouse bone marrow
    Jonas Bystrom
    NIAID, NIH, Bldg 10, Rm 11N104, 9000 Rockville Pike, Bethesda, MD, 20892, USA
    Blood 103:868-77. 2004
    ..basic protein, the ribonucleases) together with arachidonate-15-lipoxygenase and protease inhibitor plasminogen activator inhibitor 2 (PAI-2), in the IL-5-producing, infected wild-type mice only...
  95. ncbi Molecular cloning of bomapin (protease inhibitor 10), a novel human serpin that is expressed specifically in the bone marrow
    M Riewald
    Department of Vascular Biology, Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 270:26754-7. 1995
    ..The restricted expression of bomapin to the bone marrow raises the possibility that this serpin may play a role in the regulation of protease activities during hematopoiesis...
  96. ncbi Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin
    R D Ye
    Howard Hughes Medical Institute Laboratories, Washington University School of Medicine, Saint Louis, Missouri 63110
    J Biol Chem 264:5495-502. 1989
    ..We conclude that PAI-2 is the closest mammalian homologue of avian ovalbumin...
  97. ncbi Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins
    J Sun
    Department of Medicine, Monash Medical School, Clive Ward Centre, Box Hill Hospital, Australia
    J Biol Chem 270:16089-96. 1995
    ..These results suggest that PI-6 and the ov-serpin genes have diverged and do not belong to the same subgroup...
  98. ncbi Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
    V Knauper
    Department of Cell and Molecular Biology, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 4RN, United Kingdom
    J Biol Chem 271:17124-31. 1996
    ..This new activation cascade may be significant in human breast cancer pathology, where all three enzymes have been implicated as playing important roles...
  99. ncbi Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease
    Levent Kardesler
    Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey
    Clin Biochem 41:863-8. 2008
    ..To evaluate if type 2 diabetes mellitus increase gingival crevicular fluid (GCF) levels of prostaglandin E(2) (PGE(2)), interleukin-1beta (IL-1beta), tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor-2 (PAI-2)...
  100. ncbi Genetic polymorphisms and spontaneous preterm birth
    Catherine S Gibson
    School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, Australia
    Obstet Gynecol 109:384-91. 2007
    ..To examine whether selected genetic polymorphisms in the infant are associated with spontaneous preterm birth (less than 37 weeks) among children with or without later-diagnosed cerebral palsy...
  101. ncbi Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks
    B J Hunt
    Thrombosis and Vascular Biology Group, Department of Haematology, Guy s and St Thomas Trust, London, UK
    J Thromb Haemost 7:955-61. 2009
    ..An abnormal uterine artery Doppler finding is defined as early diastolic bilateral uterine artery notching (BN) in the waveform. However, about 50% of mothers with BN do not develop PET/FGR...

Research Grants3

  1. MACROPHAGE/NEUTROPHIL ELASTASE INHIBITOR
    EILEEN REMOLD O DONNELL; Fiscal Year: 1999
    ..We will analyze the functional region of the HEI-encoding gene of patients with these diseases for sequence variations using single- strand conformation polymorphism and heteroduplex analysis. ..
  2. VASOACTIVE HORMONE INDUCED GENES IN DIABETIC VASCULATURE
    EDWARD FEENER; Fiscal Year: 1999
    ....
  3. Targeting Placental Pathophysiology in IUGR and Preeclampsia
    Seth Guller; Fiscal Year: 2010
    ..However, we feel that despite modifications to the original research plan, our application provides an exciting and novel framework for elucidating pathways of placental damage in IUGR and PE. ..